報價延遲最少15分鐘:2025/01/12 05:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
28.88 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.10/2.30
|
|
企業價值
4.59B
|
| 資產負債 |
|
每股賬面淨值
1.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
233.66M
|
|
每股收益
1.22
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 05:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial. |